Kalviainen 2002

Methods	Open‐label, multicentre, randomised trial. Authors based in Denmark and Finland 2 treatment arms: CBZ (slow release) and LTG
Participants	Participants with newly onset partial and/or generalised tonic clonic seizures Number randomised: CBZ = 70, LTG = 73 No information provided about age and gender or previous AED use
Interventions	Monotherapy with CBZ or LTG for 52 weeks Mean dosage during maintenance period: CBZ = 549 mg/d, LTG = 146 mg/d Range of follow‐up not stated
Outcomes	Seizure freedom Cognitive assessments
Notes	IPD requested from trial sponsor Glaxo Smith Kline but data could not be located. Abstract publication only available
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Treatments were "randomly assigned", no further information provided
Allocation concealment (selection bias)	Unclear risk	No information provided
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No information provided
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No information provided
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Abstract only, attrition rate not stated. Insufficient information to make a judgement
Selective reporting (reporting bias)	Unclear risk	Abstract only, insufficient information to make a judgement
Other bias	Low risk	None identified